Conventional and biological therapies in atopic dermatitis – a literature review
DOI:
https://doi.org/10.12775/JEHS.2023.46.01.025Keywords
atopic dermatitis, epidermal barrier, SCORAD index, topical treatment, biological therapy, Janus kinase inhibitorsAbstract
Introduction: Atopic dermatitis is a chronic, relapsing disease with a multifactoral etiology. The basic disorder of the atopic dermatitis is the disruption of the epidermal barrier. The family history of atopy is a high risk factor of the development of the disease. The clinical manifestations are heterogeneous and vary depending on patient’s age, disease duration and current disease activity according to the SCORAD scale.
Objective: The aim of the review is to analyze the latest information on the characteristics, diagnosis and treatment of atopic dermatitis, including new biological medications.
Methods and materials: The sources available in PubMed database have been analyzed using the keywords: „atopic dermatitis”, „epidermal barrier”, „SCORAD index”, „topical treatment”, „biological therapy”, „Janus kinase inhibitors”.
Current state of knowledge: Atopic dermatitis is only treated symptomatically. The greatest therapeutic challenge is to reduce the pruritus which significantly impairs the quality of life. Topical corticosteroids may cause local side effects. The most severe cases of the disease require systemic treatment with immunosuppressants.
Conclusions: The complex pathogenesis of atopic dermatitis is the object of research. Understanding the immunological mechanisms responsible for the development of the disease allows to introduce new therapeutic options. Previous studies have confirmed the effectiveness of biological medications in reducing disease activity, which is a chance to improve the quality of live of the patients suffering from atopic dermatitis.
References
Wan H, Jia H, Xia T, Zhang D. Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: A network meta-analysis. Dermatol Ther. 2022 Sep;35(9):e15636. doi: 10.1111/dth.15636. Epub 2022 Jul 27. PMID: 35703351; PMCID: PMC9541568.
Saeki H, Ohya Y, Furuta J, Arakawa H, Ichiyama S, Katsunuma T, Katoh N, Tanaka A, Tsunemi Y, Nakahara T, Nagao M, Narita M, Hide M, Fujisawa T, Futamura M, Masuda K, Matsubara T, Murota H, Yamamoto-Hanada K; Committee for Clinical Practice Guidelines for the Management of Atopic Dermatitis 2021, The Japanese Society of Allergology, The Japanese Dermatology Association. Executive summary: Japanese guidelines for atopic dermatitis (ADGL) 2021. Allergol Int. 2022 Oct;71(4):448-458. doi: 10.1016/j.alit.2022.06.009. Epub 2022 Sep 2. PMID: 36064654.
Avena-Woods C. Overview of atopic dermatitis. Am J Manag Care. 2017 Jun;23(8 Suppl):S115-S123. PMID: 28978208.
Huang IH, Chung WH, Wu PC, Chen CB. JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review. Front Immunol. 2022 Dec 8;13:1068260. doi: 10.3389/fimmu.2022.1068260. PMID: 36569854; PMCID: PMC9773077.
Wollenberg A, Werfel T, Ring J, Ott H, Gieler U, Weidinger S. Atopic Dermatitis in Children and Adults—Diagnosis and Treatment. Dtsch Arztebl Int. 2023 Mar 31;120(13):224-234. doi: 10.3238/arztebl.m2023.0011. PMID: 36747484; PMCID: PMC10277810.
Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66 Suppl 1:8-16. doi: 10.1159/000370220. Epub 2015 Apr 24. PMID: 25925336.
2021. Allergol Int. 2022 Oct;71(4):448-458. doi: 10.1016/j.alit.2022.06.009. Epub 2022 Sep 2. PMID: 36064654.
Tamagawa-Mineoka R, Katoh N. Atopic Dermatitis: Identification and Management of Complicating Factors. Int J Mol Sci. 2020 Apr 11;21(8):2671. doi: 10.3390/ijms21082671. PMID: 32290423; PMCID: PMC7215488.
Kulthanan K, Tuchinda P, Nitiyarom R, Chunharas A, Chantaphakul H, Aunhachoke K, Chularojanamontri L, Rajatanavin N, Jirapongsananuruk O, Vichyanond P, Chatchatee P, Sangsupawanich P, Wananukul S, Singalavanija S, Trakanwittayarak S, Rerkpattanapipat T, Thongngarm T, Wisuthsarewong W, Limpongsanurak W, Kamchaisatian W, Noppakun N. Clinical practice guidelines for the diagnosis and management of atopic dermatitis. Asian Pac J Allergy Immunol. 2021 Sep;39(3):145-155. doi: 10.12932/AP-010221-1050. PMID: 34246205.
Wollenberg A, Werfel T, Ring J, Ott H, Gieler U, Weidinger S. Atopic Dermatitis in Children and Adults—Diagnosis and Treatment. Dtsch Arztebl Int. 2023 Mar 31;120(13):224-234. doi: 10.3238/arztebl.m2023.0011. PMID: 36747484; PMCID: PMC10277810.
Torres T, Ferreira EO, Gonçalo M, Mendes-Bastos P, Selores M, Filipe P. Update on Atopic Dermatitis. Acta Med Port. 2019 Sep 2;32(9):606-613. doi: 10.20344/amp.11963. Epub 2019 Sep 2. PMID: 31493365.
Dutta A, De A, Das S, Banerjee S, Kar C, Dhar S. A Cross-Sectional Evaluation of the Usefulness of the Minor Features of Hanifin and Rajka Diagnostic Criteria for the Diagnosis of Atopic Dermatitis in the Pediatric Population. Indian J Dermatol. 2021 Nov-Dec;66(6):583-590. doi: 10.4103/ijd.ijd_1046_20. PMID: 35283501; PMCID: PMC8906322.
Klasa B, Cichocka-Jarosz E. Atopic Dermatitis - Current State of Research on Biological Treatment. J Mother Child. 2020 Jul 29;24(1):53-66. doi: 10.34763/jmotherandchild.2020241.2003.0000010. PMID: 33074181; PMCID: PMC8518108.
Czarnecka-Operacz M, Jenerowicz D. Topical calcineurin inhibitors in the treatment of atopic dermatitis - an update on safety issues. J Dtsch Dermatol Ges. 2012 Mar;10(3):167-72. doi: 10.1111/j.1610-0387.2011.07791.x. Epub 2011 Oct 6. PMID: 21974750.
Wollenberg A, Werfel T, Ring J, Ott H, Gieler U, Weidinger S. Atopic Dermatitis in Children and Adults—Diagnosis and Treatment. Dtsch Arztebl Int. 2023 Mar 31;120(13):224-234. doi: 10.3238/arztebl.m2023.0011. PMID: 36747484; PMCID: PMC10277810.
Sala-Cunill A, Lazaro M, Herráez L, Quiñones MD, Moro-Moro M, Sanchez I; Skin Allergy Committee of Spanish Society of Allergy and Clinical Immunology (SEAIC). Basic Skin Care and Topical Therapies for Atopic Dermatitis: Essential Approaches and Beyond. J Investig Allergol Clin Immunol. 2018 Dec;28(6):379-391. doi: 10.18176/jiaci.0293. Epub 2018 Jul 13. PMID: 30004024.
Elias PM. Optimizing emollient therapy for skin barrier repair in atopic dermatitis. Ann Allergy Asthma Immunol. 2022 May;128(5):505-511. doi: 10.1016/j.anai.2022.01.012. Epub 2022 Jan 20. PMID: 35065300; PMCID: PMC9979622.
Galli E, Fortina AB, Ricci G, Maiello N, Neri I, Baldo E, Berti I, Bonamonte D, Capra L, Carboni E, Carello R, Caroppo F, Cavagni G, Chinellato I, Cipriani F, Comberiati P, Diociaiuti A, Di Lernia V, Duse M, Filippeschi C, Giannetti A, Giovannini M, Licari A, Marseglia GL, Pace M, Patrizi A, Pajno GB, Peroni D, Villani A, Eichenfield L. Narrative review on the management of moderate-severe atopic dermatitis in pediatric age of the Italian Society of Pediatric Allergology and Immunology (SIAIP), of the Italian Society of Pediatric Dermatology (SIDerP) and of the Italian Society of Pediatrics (SIP). Ital J Pediatr. 2022 Jun 14;48(1):95. doi: 10.1186/s13052-022-01278-7. PMID: 35701810; PMCID: PMC9195338.
Sugita K, Akdis CA. Recent developments and advances in atopic dermatitis and food allergy. Allergol Int. 2020 Apr;69(2):204-214. doi: 10.1016/j.alit.2019.08.013. Epub 2019 Oct 22. PMID: 31648922.
Ratchataswan T, Banzon TM, Thyssen JP, Weidinger S, Guttman-Yassky E, Phipatanakul W. Biologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect. J Allergy Clin Immunol Pract. 2021 Mar;9(3):1053-1065. doi: 10.1016/j.jaip.2020.11.034. PMID: 33685604; PMCID: PMC7951162.
Geba GP, Li D, Xu M, Mohammadi K, Attre R, Ardeleanu M, Musser B. Attenuating the atopic march: Meta-analysis of the dupilumab atopic dermatitis database for incident allergic events. J Allergy Clin Immunol. 2023 Mar;151(3):756-766. doi: 10.1016/j.jaci.2022.08.026. Epub 2022 Sep 7. PMID: 36084766.
Napolitano M, Fabbrocini G, Neri I, Stingeni L, Boccaletti V, Piccolo V, Amoruso GF, Malara G, De Pasquale R, Di Brizzi EV, Diluvio L, Bianchi L, Chiricozzi A, Di Guida A, Del Duca E, Moschese V, Di Lernia V, Dragoni F, Gruber M, Hansel K, Licari A, Manti S, Leonardi S, Mastorino L, Ortoncelli M, Provenzano E, Palermo A, Patella V, Peduto T, Pezzolo E, Piras V, Potestio L, Battista T, Satta R, Termine S, Palma P, Zangari P, Patruno C. Dupilumab Treatment in Children Aged 6-11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study. Paediatr Drugs. 2022 Nov;24(6):671-678. doi: 10.1007/s40272-022-00531-0. Epub 2022 Aug 27. PMID: 36028611; PMCID: PMC9417930.
Labib A, Ju T, Yosipovitch G. Managing Atopic Dermatitis with Lebrikizumab - The Evidence to Date. Clin Cosmet Investig Dermatol. 2022 Jun 8;15:1065-1072. doi: 10.2147/CCID.S295672. PMID: 35702658; PMCID: PMC9188775.
Loh TY, Hsiao JL, Shi VY. Therapeutic Potential of Lebrikizumab in the Treatment of Atopic Dermatitis. J Asthma Allergy. 2020 Feb 11;13:109-114. doi: 10.2147/JAA.S211032. PMID: 32104006; PMCID: PMC7023853.
Duggan S. Tralokinumab: First Approval. Drugs. 2021 Sep;81(14):1657-1663. doi: 10.1007/s40265-021-01583-1. Erratum in: Drugs. 2021 Sep 17;: Erratum in: Drugs. 2021 Sep 24;: PMID: 34406631; PMCID: PMC8519819.
Abduelmula A, Rankin BD, Mufti A, Yeung J, Prajapati VH. Tralokinumab for Moderate-to-Severe Atopic Dermatitis in Adults. Skin Therapy Lett. 2023 Jan;28(1):1-6. PMID: 36657434.
Tsuji G, Yamamura K, Kawamura K, Kido-Nakahara M, Ito T, Nakahara T. Novel Therapeutic Targets for the Treatment of Atopic Dermatitis. Biomedicines. 2023 Apr 27;11(5):1303. doi: 10.3390/biomedicines11051303. PMID: 37238974; PMCID: PMC10215969.
Serra-Baldrich E, Santamaría-Babí LF, Francisco Silvestre J. Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis. Actas Dermosifiliogr. 2022 Jul-Aug;113(7):674-684. English, Spanish. doi: 10.1016/j.ad.2021.12.014. Epub 2021 Dec 23. PMID: 35842249.
Kim JHK, Samra MS. Moderate to Severe Atopic Dermatitis in Children; Focusing on Th2 Cytokine Receptor Antagonists and Janus Kinase Inhibitors. Clin Exp Pediatr. 2023 Jun 14. doi: 10.3345/cep.2022.00346. Epub ahead of print. PMID: 37321570.
Tsiogka A, Kyriazopoulou M, Kontochristopoulos G, Nicolaidou E, Stratigos A, Rigopoulos D, Gregoriou S. The JAK/STAT Pathway and Its Selective Inhibition in the Treatment of Atopic Dermatitis: A Systematic Review. J Clin Med. 2022 Jul 29;11(15):4431. doi: 10.3390/jcm11154431. PMID: 35956047; PMCID: PMC9369061.
Li C., Sun X., Zhao K., Meng F., Li L., Mu Z., Han X. Efficacy and Safety of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis. Dermatology. 2022;238:725–735. doi: 10.1159/000518541.
Miot HA, Criado PR, de Castro CCS, Ianhez M, Talhari C, Ramos PM. JAK-STAT pathway inhibitors in dermatology. An Bras Dermatol. 2023 May 23:S0365-0596(23)00114-9. doi: 10.1016/j.abd.2023.03.001. Epub ahead of print. PMID: 37230920.
Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov. 2022 Jan;21(1):21-40. doi: 10.1038/s41573-021-00266-6. Epub 2021 Aug 20. PMID: 34417579; PMCID: PMC8377708.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Karolina Włodarczyk-Cybulska, Natalia Sergiel, Patrycja Maj, Piotr Mozer, Jakub Maternia, Michał Lazar, Agata Kania, Aleksandra Serwik-Trandasir, Malwina Gonet, Karolina Miszczyk
![Creative Commons License](http://i.creativecommons.org/l/by-nc-sa/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 259
Number of citations: 0